Did Populist Rage at Big Pharma Fuel Trump Victory? Election Data Indicates Maybe

I have a strong belief that Trump’s late-breaking RFK Jr. support put him on the wrong side of the political scale, causing MAGA/MAHA voter turnout.

Related: RFK Jr. Threatens War on FDA in Epic Tweet&nbsp,

There are, perhaps, a thousand points of data to wall this state, including the thundering, unprecedented reception that RFK Jr. received from the Trump crowds when he appeared alongside the past and then coming president.

But here’s an interesting another you’re certainly likely to get somewhere.

In each of the seven says below this election cycle, Trump beat his past performances, often by as much as five items.

What do these claims have in common? &nbsp,

The 340B Drug Pricing Program, the curse of Big Pharma, prevents the market from price-gouging customers in low-income hospitals, is a bill that each of them has passed at state level.

Relationship or cause? It’s difficult to tell, but the information truly permits account.

We turn to Commonwealth Fund (emphasis added ) for a succinct description of what the 340B Drug Pricing Program is and why the pharmaceutical industry might not like it.

The federal 340B Drug Pricing Program allows qualified clinics and hospitals that treat low-income and underinsured patients to purchase outpatient prescription drugs at a discount of 25 % to 50 %. The program aims to provide comprehensive services to safety-network providers who can extend their financial resources to reach more economically disadvantaged patients.

Pharmaceutical companies are alarmed about the program’s rapid growth, from 8, 100 service sites&nbsp, ( including both clinics and pharmacies ) in 2000 to 50, 000 by 2020. The Health Resources and Services Administration’s ( HRS ) released new data in August 2022, suggesting that the 340B program’s discounted purchases totaled$ 44 billion in 2021, or 16 % more than they did in 2020.

Estimated discounted substance purchases made through the 340B program in 2020 made up about 7 % of the overall U.S. drug market. According to manufacturers, pharmaceutical companies are attempting to use the discount medicine program merely to maximize their profits, which are significantly higher than those of other big public corporations.

Via Modern Healthcare (emphasis added ):

As more states pass laws to increase the scope of the project’s benefits, pharmaceutical companies are lowering their 340B drug discount restrictions.

Healthcare professionals predicted that more states will create and pass legislation to protect 340B drug discount savings&nbsp despite a lack of direction from the federal government and an 8th U.S. Circuit Court of Appeals decision affirming states ‘ authority to move in and regulate pharmacy procedures, according to healthcare professionals.

However, in Virginia, the Republican governor just signed legislation weakening the software in the position. Either through causality or accident, Trump performed worse in Virginia than in 2016.

Although we may not fully understand how much RFK Jr. is to blame for this election, the effect of his support was undoubtedly palpable.

Connected: With Trump Victory, Democrat Election Denialism Commences: What to Expect

In this way, Trump owes RFK Jr. and his supporters a bill that he can just pay back by putting him in a position with intense power and authority to create a healthier America once, using every avenue of strength applicable to the executive branch of government.

Source credit